Actively helping customers, employees and the global community during the coronavirus SARS-CoV-2 outbreak.  Learn more >>


Chemical structure for Suc-LLVY-Aminoluciferin
Chemical structure for Suc-LLVY-Aminoluciferin
Ordering information
Price ()
Catalog Number13452
Unit Size
Find Distributor
Additional ordering information
InternationalSee distributors
ShippingStandard overnight for United States, inquire for international
Physical properties
Molecular weight868.03
Spectral properties
Extinction coefficient (cm -1 M -1)18000
Excitation (nm)362
Emission (nm)499
Storage, safety and handling
H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
StorageFreeze (< -15 °C); Minimize light exposure


Molecular weight
Extinction coefficient (cm -1 M -1)
Excitation (nm)
Emission (nm)
Suc-LLVY-D-Aminolucifin is a sentive luminogenic substrate for 20S proteasome, calpains and other chymotrypsin-like proteases. Upon the protease-induced hydrolysis the non-luminescent substrate generates the luminescent D-aminoluciferin that can be easily detected with luciferase-induced luminescence. This aminoluciferin substrate is much more sensitive than the chromogenic and fluorogenic substrates. The most common form of the proteasome is known as the 26S proteasome that contains one 20S core particle structure and two 19S regulatory caps. All 20S particles consist of four stacked heptameric ring structures that are themselves composed of two different types of subunits; alpha subunits are structural in nature, whereas beta subunits are predominantly catalytic. The outer two rings in the stack consist of seven alpha subunits each, which serve as docking domains for the regulatory particles and the alpha subunits N-termini form a gate that blocks unregulated access of substrates to the interior cavity. The inner two rings each consist of seven beta subunits and contain the protease active sites that perform the proteolysis reactions.


Common stock solution preparation

Table 1. Volume of DMSO needed to reconstitute specific mass of Suc-LLVY-Aminoluciferin to given concentration. Note that volume is only for preparing stock solution. Refer to sample experimental protocol for appropriate experimental/physiological buffers.

0.1 mg0.5 mg1 mg5 mg10 mg
1 mM115.203 µL576.017 µL1.152 mL5.76 mL11.52 mL
5 mM23.041 µL115.203 µL230.407 µL1.152 mL2.304 mL
10 mM11.52 µL57.602 µL115.203 µL576.017 µL1.152 mL

Molarity calculator

Enter any two values (mass, volume, concentration) to calculate the third.

Mass (Calculate)Molecular weightVolume (Calculate)Concentration (Calculate)Moles


Open in Advanced Spectrum Viewer

Spectral properties

Extinction coefficient (cm -1 M -1)18000
Excitation (nm)362
Emission (nm)499


View all 4 citations: Citation Explorer
Diabetogenic agent alloxan is a proteasome inhibitor
Authors: Zhou, Wenjuan and Wei, Lingling and Xiao, Ting and Lai, Chunyou and Peng, Min and Xu, Lingli and Luo, Xiangwei and Deng, Shaoping and Zhang, Fengxue
Journal: Biochemical and Biophysical Research Communications (2017): 400--406
Delineation of molecular pathways involved in cardiomyopathies caused by troponin T mutations
Authors: Gilda, Jennifer E and Lai, Xianyin and Witzmann, Frank A and Gomes, Aldrin V
Journal: Molecular & Cellular Proteomics (2016): 1962--1981
Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts
Authors: Ghosh, Rajeshwary and Goswami, Sumanta K and Feitoza, Luis Felipe BB and Hammock, Bruce and Gomes, Aldrin V
Journal: International Journal of Cardiology (2016): 923--935
Advanced-glycation-end-product-induced formation of immunoproteasomes: involvement of RAGE and Jak2/STAT1
Authors: Grimm, Stefanie and Ott, Christiane and Hörlacher, Melanie and Weber, Daniela and Höhn, Annika and Grune, Tilman
Journal: Biochemical Journal (2012): 127--139


View all 36 references: Citation Explorer
Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome
Authors: Sixt SU, Adamzik M, Spyrka D, Saul B, Hakenbeck J, Wohlschlaeger J, Costabel U, Kloss A, Giesebrecht J, Dahlmann B, Peters J.
Journal: Am J Respir Crit Care Med (2009): 1098
Quinone reductase acts as a redox switch of the 20S yeast proteasome
Authors: Sollner S, Schober M, Wagner A, Prem A, Lorkova L, Palfey BA, Groll M, Macheroux P.
Journal: EMBO Rep (2009): 65
Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: The proteasome pattern as diagnostic tool for IBD patients
Authors: Visekruna A, Joeris T, Schmidt N, Lawrenz M, Ritz JP, Buhr HJ, Steinhoff U.
Journal: Inflamm Bowel Dis (2009): 526
Enzymatic properties of the 20S proteasome in wheat endosperm and its biochemical characteristics after seed imbibition
Authors: Shi C, Rui Q, Xu LL.
Journal: Plant Biol (Stuttg) (2009): 849
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
Authors: Fennell DA, Chacko A, Mutti L.
Journal: Oncogene (2008): 1189
Toward a full characterization of the human 20S proteasome subunits and their isoforms by a combination of proteomic approaches
Authors: Uttenweiler-Joseph S, Claverol S, Sylvius L, Bousquet-Dubouch MP, Burlet-Schiltz O, Monsarrat B.
Journal: Methods Mol Biol (2008): 111
Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus
Authors: Majetschak M, Perez M, Sorell LT, Lam J, Maldonado ME, Hoffman RW.
Journal: Clin Vaccine Immunol (2008): 1489
The 20S proteasome of Schistosoma mansoni: a proteomic analysis
Authors: Castro-Borges W, Cartwright J, Ashton PD, Braschi S, Guerra Sa R, Rodrigues V, Wilson RA, Curwen RS.
Journal: Proteomics (2007): 1065
Design and synthesis of a novel class of furan-based molecules as potential 20S proteasome inhibitors
Authors: Fu Y, Xu B, Zou X, Ma C, Yang X, Mou K, Fu G, Lu Y, Xu P.
Journal: Bioorg Med Chem Lett (2007): 1102
beta-Subunit appendages promote 20S proteasome assembly by overcoming an Ump1-dependent checkpoint
Authors: Li X, Kusmierczyk AR, Wong P, Emili A, Hochstrasser M.
Journal: Embo J (2007): 2339